Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future
Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.
You may also be interested in...
Investor Eye: What's Changing In Medtech Deal Making As We Approach The End Of 2022?
Kristen Pothier, global lead of KPMG’s health care and life sciences advisory service, spoke to Medtech Insight about the current deal making climate, and how it impacts the diagnostics sector.
CobiCure Will Develop Cardiac Devices For Children, Sans Profit Motive
CobiCure is pursuing a non-profit approach to the development of cardiac devices for underserved patient populations.
AstraZeneca And Huma On Digital’s Value For Pharma
Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.